204 related articles for article (PubMed ID: 26812792)
21. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions.
Graziani MS; Merlini G
Expert Rev Mol Diagn; 2014 Jan; 14(1):55-66. PubMed ID: 24308339
[TBL] [Abstract][Full Text] [Related]
22. Immunoglobulin heavy light chain test quantifies clonal disease in patients with AL amyloidosis and normal serum free light chain ratio.
Prokaeva T; Spencer B; Sun F; O'Hara RM; Seldin DC; Connors LH; Sanchorawala V
Amyloid; 2016 Dec; 23(4):214-220. PubMed ID: 27677679
[TBL] [Abstract][Full Text] [Related]
23. [New possibilities of the diagnosis and monitoring of the course of AL-amyloidosis].
Rameev VV; Kozlovskaia LV; Kogarko IN; Kogarko BS
Ter Arkh; 2010; 82(6):29-32. PubMed ID: 20731106
[TBL] [Abstract][Full Text] [Related]
24. Utility of the Serum Free Light Chain Assay in the Diagnosis of Light Chain Amyloidosis in Patients With Heart Failure.
Chang IC; Dispenzieri A; Scott CG; Lin G; Jaffe AS; Klarich KW; Grogan M
Mayo Clin Proc; 2019 Mar; 94(3):447-454. PubMed ID: 30718069
[TBL] [Abstract][Full Text] [Related]
25. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis.
Palladini G; Campana C; Klersy C; Balduini A; Vadacca G; Perfetti V; Perlini S; Obici L; Ascari E; d'Eril GM; Moratti R; Merlini G
Circulation; 2003 May; 107(19):2440-5. PubMed ID: 12719281
[TBL] [Abstract][Full Text] [Related]
26. The challenge of systemic immunoglobulin light-chain amyloidosis (Al).
Palladini G; Comenzo RL
Subcell Biochem; 2012; 65():609-42. PubMed ID: 23225018
[TBL] [Abstract][Full Text] [Related]
27. Decrease of B-type natriuretic peptide to less than 200 pg/mL predicts longer survival in cardiac immunoglobulin light chain amyloidosis.
Ishiguro K; Hayashi T; Igarashi T; Maruyama Y; Ikeda H; Ishida T; Shinomura Y
Int J Hematol; 2015 Aug; 102(2):200-4. PubMed ID: 26016720
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis.
Bochtler T; Hegenbart U; Heiss C; Benner A; Cremer F; Volkmann M; Ludwig J; Perz JB; Ho AD; Goldschmidt H; Schonland SO
Haematologica; 2008 Mar; 93(3):459-62. PubMed ID: 18287137
[TBL] [Abstract][Full Text] [Related]
29. Different NT-proBNP circulating levels for different types of cardiac amyloidosis.
Perfetto F; Bergesio F; Grifoni E; Fabbri A; Ciuti G; Frusconi S; Angelotti P; Spini V; Cappelli F
J Cardiovasc Med (Hagerstown); 2016 Nov; 17(11):810-7. PubMed ID: 26765991
[TBL] [Abstract][Full Text] [Related]
30. Discordance between serum cardiac biomarker and immunoglobulin-free light-chain response in patients with immunoglobulin light-chain amyloidosis treated with immune modulatory drugs.
Dispenzieri A; Dingli D; Kumar SK; Rajkumar SV; Lacy MQ; Hayman S; Buadi F; Zeldenrust S; Leung N; Detweiler-Short K; Lust JA; Russell SJ; Kyle RA; Gertz MA
Am J Hematol; 2010 Oct; 85(10):757-9. PubMed ID: 20872958
[TBL] [Abstract][Full Text] [Related]
31. Longitudinal left ventricular function for prediction of survival in systemic light-chain amyloidosis: incremental value compared with clinical and biochemical markers.
Buss SJ; Emami M; Mereles D; Korosoglou G; Kristen AV; Voss A; Schellberg D; Zugck C; Galuschky C; Giannitsis E; Hegenbart U; Ho AD; Katus HA; Schonland SO; Hardt SE
J Am Coll Cardiol; 2012 Sep; 60(12):1067-76. PubMed ID: 22883634
[TBL] [Abstract][Full Text] [Related]
32. Midregional proadrenomedullin (MR-proADM) is a powerful predictor of early death in AL amyloidosis.
Palladini G; Barassi A; Perlini S; Milani P; Foli A; Russo P; Albertini R; Obici L; Lavatelli F; Sarais G; Casarini S; Moratti R; Melzi d'Eril GV; Merlini G
Amyloid; 2011 Dec; 18(4):216-21. PubMed ID: 22070520
[TBL] [Abstract][Full Text] [Related]
33. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation.
Dispenzieri A; Lacy MQ; Katzmann JA; Rajkumar SV; Abraham RS; Hayman SR; Kumar SK; Clark R; Kyle RA; Litzow MR; Inwards DJ; Ansell SM; Micallef IM; Porrata LF; Elliott MA; Johnston PB; Greipp PR; Witzig TE; Zeldenrust SR; Russell SJ; Gastineau D; Gertz MA
Blood; 2006 Apr; 107(8):3378-83. PubMed ID: 16397135
[TBL] [Abstract][Full Text] [Related]
34. Optimization of Serum Immunoglobulin Free Light Chain Analysis for Subclassification of Cardiac Amyloidosis.
Halushka MK; Eng G; Collins AB; Judge DP; Semigran MJ; Stone JR
J Cardiovasc Transl Res; 2015 Jun; 8(4):264-8. PubMed ID: 25925232
[TBL] [Abstract][Full Text] [Related]
35. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias.
Mayo MM; Johns GS
Contrib Nephrol; 2007; 153():44-65. PubMed ID: 17075223
[TBL] [Abstract][Full Text] [Related]
36. Immunofixation electrophoresis was highly specific for the diagnosis of renal light-chain amyloidosis.
Zhou FD; Zhang LX; Yao Y; Wang SX; Zou WZ; Liu G; Chen M; Zhao MH
Am J Med Sci; 2013 Jan; 345(1):18-21. PubMed ID: 22627261
[TBL] [Abstract][Full Text] [Related]
37. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: a pilot study.
Kaplan B; Golderman S; Aizenbud B; Esev K; Kukuy O; Leiba M; Livneh A; Ben-Zvi I
Am J Hematol; 2014 Sep; 89(9):882-8. PubMed ID: 24866208
[TBL] [Abstract][Full Text] [Related]
38. Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.
Kumar SK; Gertz MA; Dispenzieri A
J Clin Oncol; 2019 Jan; 37(2):171-173. PubMed ID: 30433848
[No Abstract] [Full Text] [Related]
39. Natural history and therapy of AL cardiac amyloidosis.
Grogan M; Dispenzieri A
Heart Fail Rev; 2015 Mar; 20(2):155-62. PubMed ID: 25447844
[TBL] [Abstract][Full Text] [Related]
40. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
